Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Investing.com -- Novartis (SIX:NOVN) hiked its full-year earnings outlook on Tuesday, driven by strong demand for key therapies including Leqvio, Kisqali, and Kesimpta in the first quarter.
The Swiss pharmaceutical company now expects its 2025 operating income, excluding special items, to increase by a "low double-digit" percentage. That marks an upgrade from its earlier guidance for "high single to low double-digit" growth, and follows a 22% rise in 2024.
First-quarter net income, adjusted for one-time items, climbed 22% to $4.48 billion, exceeding analyst expectations of roughly $4.2 billion.
Among the top-performing products, Kisqali—used in breast cancer treatment—posted a 52% jump in quarterly revenue to $956 million.
Sales of Leqvio, a cholesterol-lowering drug, surged 70% to $257 million, showing improved traction following a sluggish initial rollout.
Earlier this month, Novartis unveiled a $23 billion investment plan to build and expand ten manufacturing sites across the U.S. The move comes amid growing concerns about potential drug import tariffs under U.S. President Donald Trump’s trade policy.